These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37639063)

  • 1. Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case-control study.
    Sui L; Yan Y; Jiang T; Ou D; Chen C; Lai M; Ni C; Zhu X; Wang L; Yang C; Li W; Yao J; Xu D
    Breast Cancer Res Treat; 2023 Nov; 202(1):45-55. PubMed ID: 37639063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
    Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined conventional ultrasonography with clinicopathological features to predict axillary status after neoadjuvant therapy for breast cancer: A case-control study.
    Yan Y; Jiang T; Sui L; Ou D; Qu Y; Chen C; Lai M; Ni C; Liu Y; Wang Y; Xu D
    Br J Radiol; 2023 Dec; 96(1152):20230370. PubMed ID: 37750854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study.
    Liu Y; Wang Y; Wang Y; Xie Y; Cui Y; Feng S; Yao M; Qiu B; Shen W; Chen D; Du G; Chen X; Liu Z; Li Z; Yang X; Liang C; Wu L
    EClinicalMedicine; 2022 Oct; 52():101562. PubMed ID: 35928032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
    Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
    Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study.
    Tang L; Shu X; Tu G
    World J Surg Oncol; 2022 Jan; 20(1):27. PubMed ID: 35093083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
    Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
    Front Immunol; 2022; 13():877825. PubMed ID: 35663978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram based on quantitative dynamic contrast-enhanced magnetic resonance imaging, apparent diffusion coefficient, and clinicopathological features for early prediction of pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy.
    He M; Su J; Ruan H; Song Y; Ma M; Xue F
    Quant Imaging Med Surg; 2023 Jul; 13(7):4089-4102. PubMed ID: 37456283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study.
    Tang L; Li Z; Jiang L; Shu X; Xu Y; Liu S
    Front Oncol; 2022; 12():999716. PubMed ID: 36605428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
    Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
    Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models.
    Suo S; Yin Y; Geng X; Zhang D; Hua J; Cheng F; Chen J; Zhuang Z; Cao M; Xu J
    J Transl Med; 2021 Jun; 19(1):236. PubMed ID: 34078388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
    Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS
    Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
    Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model combining BI-RADS® descriptors from pre-treatment B-mode breast ultrasound with clinicopathological tumor features shows promise in the prediction of residual disease after neoadjuvant chemotherapy.
    Kapetas P; Aggarwal R; Altuwayjiri B; Pinker K; Clauser P; Helbich TH; Baltzer PAT
    Eur J Radiol; 2024 Sep; 178():111649. PubMed ID: 39094464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
    Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
    Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
    Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
    Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.